Early-Stage Lung Cancer: Refining Treatment PlansAugust 26th 2014
The optimal management of patients with early-stage NSCLC remains controversial, and the prospect of exposing an otherwise low-risk patient to potentially toxic chemotherapy based on limited prognostic information remains a problem for many clinicians.
Aligning High Science With Health CareAugust 8th 2014
New and evolving strategies for clinical trial design are under way, a point that was made abundantly clear April 25th at the NCCN Policy Summit on Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies.
A New Concept to Broaden Access to Molecular TestingAugust 6th 2014
During a 2013 discussion on treating NSCLC, a group of oncologists were asked what share of cancer patients have access to molecular testing. The answers varied: One said he guessed 40% to 50%, another said "a large minority."
Veliparib Shows Responses in Ovarian CancerJune 23rd 2014
Major objective responses to treatment were demonstrated in one-fourth of patients with relapsed or refractory BRCA-mutant ovarian cancer with the investigational PARP inhibitor, veliparib, according to results from a phase II study.